VIRAX BIOLABS GROUP LTD
VRAXNASDAQTrading Snapshot
- Day Range
- $2.85 – $2.89
- 52-Week Range
- $2.50 – $21.75
- Volume
- $3.52B
- Avg Volume
- $2.61B
- Shares Outstanding
- 186,625
- Next Earnings
- Oct 28, 2026
Fundamentals Snapshot
- Annual Revenue
- $12,423
- Last Q Revenue
- $12,423
- P/E Ratio
- -0.1
- P/S Ratio
- 38.2x
- EPS (TTM)
- $-18.52
- Dividend Yield
- 0.00%
Why Investors Own VRAX
- ✓High-growth profile — revenue up +24.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 75% gross margin and 9% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About VIRAX BIOLABS GROUP LTD
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Virax Biolabs Files Prospectus For Offering 1.682M Ordinary Shares
https://www.sec.gov/Archives/edgar/data/1885827/000119312526316130/vrax-20260724.htm
Get insights into the top gainers and losers of Thursday's pre-market session.
As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers AtaiBeckley (NASDAQ:ATAI) stock rose 34.3% to $7.2 during Thursday's pre-market session. The market value of their outstanding shares is at $1.9 billion. Agape ATP (NASDAQ:ATPC) shares moved upwards by
Virax Biolabs Management Believes Current Valuation Doesn't Fully Reflect Its Audited Financial Position, Clinical And Development Programs, Commercial Progress Or Strategic Assets
Dear Fellow Shareholders,Following several significant developments in recent weeks, I wanted to provide shareholders with a concise update on Virax's current position and priorities.Our fiscal 2026 Annual Report